BioCentury
ARTICLE | Finance

Family time

Why Dragonfly seeks family offices and strategic partners over traditional VCs

June 16, 2017 7:37 PM UTC

With funding from family offices and now a new deal with Celgene Corp. (NASDAQ:CELG), Dragonfly Therapeutics Inc. says it will not need traditional VC financing to bring its first cancer therapy into the clinic.

CEO Bill Haney told BioCentury Dragonfly prefers funding from family offices, especially those driven by a mission rather than an exit timeline. ...

BCIQ Company Profiles

Dragonfly Therapeutics Inc.